| Konjen et al. (2015) | Thailand | 30 | rESWT(15), Ultrasound(15) | rESWT: 45.6±1.07,US: 45.0±1.13 | rESWT: 4/11, US: 2/13 | 1.33-1.37 years |
| Rompe et al. (2015) | Germany | 152 | Only rESWT(73),rESWT+stretching(79) | Only rESWT: 51.2(27-71),rESWT+stretching: 52.0(30-73) | Only rESWT: 33/40,rESWT+stretching: 38/41 | Only rESWT: 18 months(12-34),rESWT+stretching: 16 months(12-30) |
| Eslamian et al. (2016) | Iran | 40 | rESWT(20),CS injection(20) | rESWT: 41.45±8.05,CS injection: 42.85±8.62 | rESWT: 2/18,CS injection: 5/15 | 8wks(>2 months conservative treatment failure) |
| Hocaoglu et al. (2017) | Turkey | 72 | rESWT(36), Corticosteroid(36) | rESWT: 50.22±8.29, Corticosteroid: 47.86±7.90 | rESWT: 6/30, Corticosteroid: 4/32 | 8-9 months |
| Ibrahim et al. (2017) | USA | 52(50 completed) | rESWT(25),Placebo(25) | rESWT: 56.6±2.7,Placebo: 49.1±2.6 | rESWT: 9/18,Placebo: 11/14 | ≥6 months |
| Ulusoy et al. (2017) | Turkey | 60 | LLLT(20),US therapy(20),rESWT(20) | LLLT: 53.40±14.71,US therapy: 50.95±9.62,rESWT: 54.45±6.90 | LLLT: 4/16,US therapy: 3/17,rESWT: 4/16 | LLLT: 14.40±9.00 months,US therapy: 17.30±14.71 monthsrESWT: 27.00±29.79 months |
| Yin et al.(2017) | China | 278 | rESWT low(93), moderate(93),high(92) | 55.0±13.3 | 142/136 | 82.1 days(30-365 days) |
| Uğurlar et al. (2018) | Turkey | 158 | rESWT(39)Prolotherapy(40)PRP(39)CS injection(40) | rESWT: 39.2(21-49Prolotherapy: 37.5(25-62)PRP: 38.4(19-58) injection: 40.1(21-56) | rESWT: 22/17Prolotherapy: 21/19PRP: 19/20CS injection: 17/23 | rESWT: 15.7 months(14-18)Prolotherapy: 13.2 months(12-14)PRP: 13.9 months(12-15)CS injection: 14.5 months(13-16) |
| Morral Fernández et al. (2019) | Spain | 135 | Standard rESWT device(45)Sophisticated rESWT device(45)Austere rESWT device(45) | Standard rESWT device: 48.27±9.96Sophisticated rESWT device: 52.51±12.28Austere rESWT device: 49.31±11.14 | Standard rESWT device: 30/15Sophisticated rESWT device: 18/27Austere rESW device: 22/23 | Standard rESWT device: 13.27±9.26 monthsSophisticated rESWT device: 14.98±12.72 monthsAustere rESW device: 13.53±9.09 months |
| Asheghan et al. (2021) | Iran | 59 | rESWT(29), Prolotherapy(30) | Not specified | rESWT: 9/20, Prolotherapy: 11/19 | >8 weeks |
| Mohammed et al. (2022) | Iraq | 50 | rESWT(25),Steroid injection(25) | rESWT: 35.2(28-44),Steroid injection: 30.9(25-45) | rESWT: 8/17,Steroid injection: 7/18 | ≥6 months (failed conservative treatment) |
| Wheeler et al. (2022) | UK | 117(114 completed) | Intervention(60),Control(55) | Intervention: 50.3±9.2,Control: 53.2±9.8 | Intervention: 24/36,Control: 16/41 | 32.6±30.8 months(Median: 24 months) |
| Moneim et al. (2023) | Egypt | 50 | rESWT(25)CSI+TUS(25) | rESWT: 45.4±10.8,CSI+TUS: 40.0±7.3 | Female only(0/50) | >3 months |
| Orhan et al. (2023) | Turkey | 90 feet(64 patients) | CSI(30),rESWT(30),KT(30) | Total: 38.3±10.4,CSI: 37.1±9.1,rESWT: 37.3±10.9,KT: 40.4±11.2 | Total: 11/53,CSI: 3/19,rESWT: 4/18,KT: 4/16 | 6 month |
| On & Yim|(2023) | Republic of Korea | 34 | rESWT-LV(17),rESWT-alone(17) | 37.5 | Not specified | >3 months |
| RIAZ et al.(2023) | Pakistan | 45 | rESWT: 15,HILT: 15,Control: 15 | rESWT: 39.66±10.05,HILT: 38.06±12.64,Control: 37.40±13.18 | Total: 17/28 | having a duration of symptoms of more than 6 months |
| Pabón-Carrasco et al. (2024) | Spain | 127 | Iontophoresis(63),rESWT(64) | Iontophoresis: 51.5±11.6,rESWT: 48.8±8.7 | Iontophoresis: 36/26rESWT: 35/30 | >8 weeks (chronic PF, >3mm fascia thickness) |
| Wang et al.(2024) | China | 86(80 completed) | rESWT+Trps(40),rESWT(40) | rESWT+Trps: 50.3±9.2,rESWT: 53.2±9.8 | rESWT+Trps: 16/24,rESWT: 14/26 | rESWT+Trps: 33.4±36.3 months,rESWT: 31.9±24.7 months |
| Ines et al.(2025) | Tunisia | 129 | rESWT(66),Physio+US(63) | rESWT: 50.6±10.92,Physio+US: 50±9 | rESWT: 19/47,Physio+US: 9/54 | rESWT: 11 months (12.3 SD),Physio+US: 10.8 months (10.5 SD) |